Advancing InterventionalPsychiatry – Together

We provide the technology, teams, and services you need to launch and scale a successful program, with no upfront capital required

Proven Track Record

200K+

Interventional Treatments

Successfully managed by our team

$100M+

Psychiatry Revenue

Managed by our team nationwide

Treatments We Support

Enhance outcomes and revenue with FDA-approved interventional psychiatry treatments

Transcranial Magnetic Stimulation (TMS)

FDA-approved, non-invasive brain stimulation device

FDA-approved for treatment-resistant depression, OCD, migraine aura, and smoking cessation

Covered by most insurance plans

60–70% response rate with minimal side effects

Transcranial Magnetic Stimulation (TMS)

FDA-approved, non-invasive brain stimulation device

•FDA-approved for treatment-resistant depression, OCD, migraine aura, and smoking cessation

•Covered by most insurance plans

•60–70% response rate with minimal side effects

Transcranial Magnetic Stimulation (TMS)

Spravato® (Esketamine)

First FDA-approved ketamine-derived treatment for depression

FDA-approved for treatment-resistant depression and depression with suicidal ideation

Covered by most insurance plans

60–70% response rate with minimal side effects

Spravato® (Esketamine)

First FDA-approved ketamine-derived treatment for depression

•FDA-approved for treatment-resistant depression and depression with suicidal ideation

•Covered by most insurance plans

•60–70% response rate with minimal side effects

Spravato® (Esketamine)

Transcranial Magnetic Stimulation (TMS)

FDA-approved, non-invasive brain stimulation device

FDA-approved for treatment-resistant depression, OCD, migraine aura, and smoking cessation

Covered by most insurance plans

60–70% response rate with minimal side effects

Transcranial Magnetic Stimulation (TMS)

FDA-approved, non-invasive brain stimulation device

•FDA-approved for treatment-resistant depression, OCD, migraine aura, and smoking cessation

•Covered by most insurance plans

•60–70% response rate with minimal side effects

Transcranial Magnetic Stimulation (TMS)

Spravato® (Esketamine)

First FDA-approved ketamine-derived treatment for depression

FDA-approved for treatment-resistant depression and depression with suicidal ideation

Covered by most insurance plans

60–70% response rate with minimal side effects

Spravato® (Esketamine)

First FDA-approved ketamine-derived treatment for depression

•FDA-approved for treatment-resistant depression and depression with suicidal ideation

•Covered by most insurance plans

•60–70% response rate with minimal side effects

Spravato® (Esketamine)

Why Practices Choose Careforce

Our comprehensive platform eliminates operational barriers to offering interventional psychiatric treatments

Superior Clinical Outcomes

We help deliver up to 2x higher remission rates through proven interventional treatments

Turnkey, Capital-Free Launch

We provide the staff, devices, and operational support with zero upfront investment

End-to-End Management

We handle everything from eligibility to billing, leveraging experience from 200k+ treatments

Proven Revenue Growth

Partners can earn >$100k in incremental take-home per prescriber annually

Everything You Need to Launch, Manage, and Grow Interventional Psychiatry

A single, integrated platform that removes all barriers to offering TMS and Spravato® services

Patient Engagement

AI scans EHR, Patient Advocates onboard eligible patients

Revenue Cycle Management

AI enabled prior auths, claims, denials, and collections

Staffing and Equipment

Certified staff, devices, and training with no upfront cost

Compliance and Operations

DEA, REMS, and HIPAA managed end-to-end

Our Team Brings Deep Expertise

Experienced professionals dedicated to transforming mental health

Ben Kuhn

Co-founder & CEO

Healthcare leader with 20+ years scaling MSOs to over $1B in revenue.

Ginger Holguin

Head of Clinical Ops

Psychiatric care leader with 20+ years, managing $100M+ across 9 national markets.

John Fleming MD

Chief Medical Officer

Psychiatrist with 50+ years' experience and 80K+ interventional treatments delivered.

Daniel Judd

Co-founder & Head of Sales

Experienced healthcare operator & venture builder with experience launching 130 companies

E. Mertens

Director of RCM

RCM veteran with 30+ years optimizing revenue for 100+ healthcare groups.

Ashish Sharma

VP Technology

Tech operator who built a conversational AI startup from scratch to acquisition

Join leading Mental Health Providers who have transformed patient outcomes and practice growth with CareforceJoin leading Mental Health Providers who have transformed patient outcomes and practice growth with advanced TMS and Spravato® services

No commitment required. 30-minute consultation.